Drugs for Lymphoma

Table. Drugs Prescribed for Lymphoma

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Adcetris (brentuximab vedotin)
Drug company
• Seagen
Indication
• Treatment of classical Hodgkin lymphoma
  
  Treatment of classical Hodgkin lymphoma in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma
Patient support services
• Seagen Secure Patient Assistance Program
  855-473-2873

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indication
• Treatment of adults with relapsed or refractory classical Hodgkin lymphoma
  
  Treatment of pediatric patients with refractory classical Hodgkin lymphoma, or classical Hodgkin lymphoma who have relapsed after 2 or more lines of therapy
Patient support services
• Merck Co-pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Opdivo (nivolumab)
Drug company
• Bristol Myers Squibb
Indication
• Treatment of adults with classical Hodgkin lymphoma who have relapsed or progressed after autologous stem-cell transplant and Bendeka, or after 3 or more lines of systemic therapy that included autologous transplant
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Adcetris (brentuximab vedotin)
Drug company
• Seagen
Indication
• Treatment of systemic anaplastic large-cell lymphoma or other CD30- expressing peripheral T-cell lymphomas, alone or in combination with cyclophosphamide, doxorubicin, and prednisone
  
  Treatment of primary cutaneous anaplastic large-cell lymphoma, or CD30-expressing mycosis fungoides, after systemic therapy
Patient support services
• Seagen Secure Patient Assistance Program
  855-473-2873

Drug name (generic name)
• Beleodaq (belinostat) Injection
Drug company
• Acrotech Biopharma
Indication
• Treatment of relapsed or refractory peripheral T-cell lymphoma (a type of NHL)
Patient support services
• STAR Co-pay Assistance
  888-537-8277
  
  STAR Patient Assistance Program
  888-537-8277

Drug name (generic name)
• Bendeka (bendamustine HCl) Injection
Drug company
• Teva
Indication
• Treatment of indolent B-cell NHL progressing during or within 6 months of Rituxan treatment or Rituxan-containing regimen
Patient support services
• Teva Cares Foundation Patient Assistance Program
  877-237-4881

Drug name (generic name)
• Brukinsa (zanubrutinib) Capsules
Drug company
• BeiGene
Indication
• Treatment of adults with Waldenström’s macroglobulinemia, a rare type of NHL
Patient support services
• BeiGene Co-pay Assistance
  833-234-4363
  
  BeiGene Bridge Supply Program
  833-234-4363
  
  BeiGene Free Product Assistance
  833-234-4363

Drug name (generic name)
• Folotyn (pralatrexate)
Drug company
• Acrotech Biopharma
Indication
• Treatment of relapsed or refractory peripheral T-cell lymphoma (a type of NHL)
Patient support services
• STAR Co-pay Assistance
  888-537-8277
  
  STAR Patient Assistance Program
  888-537-8277

Drug name (generic name)
• Imbruvica (ibrutinib) Capsules/Tablets
Drug company
• Pharmacyclics
Indication
• Treatment of Waldenström’s macroglobulinemia (a rare type of NHL)
Patient support services
• Imbruvica By Your Side Program
  888-968-7743
  
  Johnson & Johnson Patient Assistance Foundation
  800-652-6227

Drug name (generic name)
• Mozobil (plerixafor) Injection
Drug company
• Sanofi Aventis
Indication
• Treatment of NHL, in combination with granulocyte colony-stimulating factor
Patient support services
• Sanofi Patient Assistance Connection
  888-847-4877
  

Drug name (generic name)
• Poteligeo (mogamulizumab-kpkc)
Drug company
• Kyowa Kirin
Indication
• Treatment of relapsed fungoides or refractory mycosis (a type of NHL)
  
  Treatment of Sézary syndrome (a type of NHL)
Patient support services
• Kyowa Kirin Cares Co-Pay Assistance Program
  833-552-2737
  
  Kyowa Kirin Cares Patient Assistance Program
  833-552-2737

Drug name (generic name)
• Rituxan (rituximab)
Drug company
• Genentech
Indication
• Treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  
  First-line treatment of follicular, CD20-positive, B-cell NHL, in combination with firstline chemotherapy, and, in patients achieving a complete or partial response to a rituximab drug, in combination with chemotherapy, as single-agent maintenance therapy
  
  Treatment of nonprogressing, low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line chemotherapy, and for first-line treatment of diffuse large B-cell, CD20-positive NHL, in combination with anthracycline-based chemotherapy regimens
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) Injection
Drug company
• Jazz Pharmaceuticals
Indication
• Treatment of acute lymphoblastic lymphoma in patients aged 1 month or older with hypersensitivity to E. coli–derived asparaginase
Patient support services
• Savings Card
  833-533-5299
  
  Patient Assistance Program
  833-533-5299

Drug name (generic name)
• Truxima (rituximab-abbs)
Drug company
• Teva
Indication
• Treatment of relapsed or refractory low-grade or follicular CD20-positive B-cell NHL
  
  Treatment of untreated follicular CD20-positive B-cell NHL, in combination with first-line chemotherapy
  
  Treatment of nonprogressing, low-grade, CD20-positive, B-cell NHL
Patient support services
• Truxima Patient Savings Program
  888-587-3263
  
  Teva Cares Foundation Patient Assistance Program
  877-237-4881

Drug name (generic name)
• Valchlor (mechlorethamine) Topical Gel
Drug company
• Helsinn
Indication
• Treatment of stage IA/IB mycosis fungoides-type cutaneous T-cell lymphoma
Patient support services
• Valchlor Co-pay Program
  855-482-5245

Drug name (generic name)
• Xalkori (crizotinib) Capsules
Drug company
• Pfizer
Indication
• Treatment of patients aged 1 to 21 years with relapsed or refractory systemic anaplastic large-cell lymphoma (a rare type of NHL) and ALK mutation
Patient support services
• Pfizer Oncology Together Co-Pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Yescarta (axicabtagene ciloleucel)
Drug company
• Kite Pharma
Indication
• Treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (a type of NHL), after at least 2 systemic therapies
  
  Treatment of relapsed or refractory high-grade B-cell lymphoma (a type of NHL), after at least 2 systemic therapies
Patient support services
• Kite Konnect
  844-454-5483

Drug name (generic name)
• Zolinza (vorinostat) Capsles
Drug company
• Merck
Indication
• Treatment of cutaneous T-cell lymphoma (a type of NHL) that is progressive, persistent, or recurrent, with or after 2 systemic therapies
Patient support services
• Merck Patient Assistance Program
  800-727-5400

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Rituxan (rituximab)
Drug company
• Genentech
Indication
• Treatment of pediatric patients 6 months to 18 years of age, in combination with chemotherapy, with previously untreated, advanced stage, CD20-positive DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Breyanzi (lisocabtagene maraleucel)
Drug company
• Juno Therapeutics
Indication
• Treatment of adult patients with LBCL, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to firstline chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for HSCT due to comorbidities or age; or relapsed or refractory disease after 2 or more lines of systemic therapy
Patient support services
• Cell Therapy 360 Copay Program
  888-805-4555
  
  Cell Therapy 360 Patient Assistance Program
  888-805-4555

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indication
• Treatment of patients with refractory primary mediastinal large B-cell lymphoma, or patients whose disease relapsed after 2 or more therapies
Patient support services
• Merck Co-pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Kymriah (tisagenlecleucel)
Drug company
• Novartis
Indication
• Treatment of relapsed or refractory large B-cell lymphoma after 2 or more systemic therapies, including DLBCL not specified
  
  High-grade B-cell lymphoma
  
  DLBCL arising from follicular lymphoma
Patient support services
• Kymriah Cares
  844-459-6742

Drug name (generic name)
• Monjuvi (tafasitamab-cxix)
Drug company
• MorphoSys
Indication
• Treatment, in combination with Revlimid, of adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low-grade lymphoma, who are not eligible for autologous stem-cell transplant
Patient support services
• My Mission Support Copay Assistance Program
  855-421-6172
  
  MorphoSys Foundation Patient Assistance Program
  855-421-6172

Drug name (generic name)
• Polivy (polatuzumab vedotin-piiq) Injection
Drug company
• Genentech
Indication
• Treatment of relapsed or refractory DLBCL, after at least 2 therapies, in combination with Bendeka and Rituxan
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Rituxan (rituximab)
Drug company
• Genentech
Indication
• Treatment of pediatric patients 6 months to 18 years, in combination with chemotherapy, with previously untreated, advanced stage, CD20-positive DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Rituxan Hycela (rituximab/ hyaluronidase human) Injection
Drug company
• Genentech
Indication
• Untreated DLBCL, in combination with a chemotherapy regimen
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Yescarta (axicabtagene ciloleucel)
Drug company
• Kite Pharma
Indication
• Treatment of relapsed or refractory large DLBCL not otherwise specified, after at least 2 systemic therapies
  
  Relapsed or refractory DLBCL arising from follicular lymphoma, after at least 2 systemic therapies
  
  Treatment of adult patients with DLBCL that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy
Patient support services
• Kite Konnect
  844-454-5483

Drug name (generic name)
• Zynlonta (loncastuximab tesirine-lpyl) Injection
Drug company
• ADC Therapeutics
Indication
• Treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including DLBCL not otherwise specified; DLBCL arising from low-grade lymphoma; and high-grade B-cell lymphoma
Patient support services
• ADVANCING Patient Support Copay Assistance Program
  855-690-0340
  
  ADVANCING Patient Assistance Program
  855-690-0340

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Aliqopa (copanlisib) Injection
Drug company
• Bayer
Indication
• Treatment of adults with relapsed follicular lymphoma, after at least 2 systemic therapies
Patient support services
• Aliqopa $0 Co-Pay Program
  833-254-7672
  
  Bayer US Patient Assistance Foundation
  866-228-7723

Drug name (generic name)
• Breyanzi (lisocabtagene maraleucel)
Drug company
• Juno Therapeutics
Indication
• Treatment of adult patients who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for HSCT due to comorbidities or age
  
  Treatment of adult patients who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for HSCT due to comorbidities or age
Patient support services
• Cell Therapy 360 Copay Program
  888-805-4555
  
  Cell Therapy 360 Patient Assistance Program
  888-805-4555

Drug name (generic name)
• Gazyva (obinutuzumab)
Drug company
• Genentech
Indication
• Follicular lymphoma, in combination with bendamustine followed by Gazyva alone, in patients whose disease relapsed after, or is refractory to, a rituximab-containing regimen
  
  Untreated advanced follicular lymphoma, in combination with chemotherapy followed by Gazyva alone, in patients achieving a partial remission
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Kymriah (tisagenlecleucel)
Drug company
• Novartis
Indication
• Treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy
Patient support services
• Kymriah Cares
  844-459-6742

Drug name (generic name)
• Revlimid (lenalidomide) Capsules
Drug company
• Bristol Myers Squibb
Indication
• Treatment of previously treated follicular lymphoma, in combination with Rituxan or its biosimilar
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Rituxan Hycela (rituximab/ hyaluronidase human) Injection
Drug company
• Genentech
Indication
• Relapsed or refractory follicular lymphoma, as a single drug
  
  Untreated follicular lymphoma, in combination with first-line chemotherapy
  
  Maintenance therapy of follicular lymphoma, as a single drug, in patients with complete or partial response to rituximab plus chemotherapy
  
  Nonprogressing or stable follicular lymphoma, after first-line chemotherapy
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Tazverik (tazemetostat) Tablets
Drug company
• Epizyme
Indication
• Treatment of adults with relapsed or refractory follicular lymphoma and EZH2 mutation, as detected by an FDA-approved test, after at least 2 previous systemic therapies
  
  Treatment of adults with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options
Patient support services
• Co-Pay Assistance Program
  833-437-4669
  
  Patient Assistance Program
  833-437-4669
  
  Bridge Supply Program
  833-437-4669
  
  Quick Start Program
  833-437-4669

Drug name (generic name)
• Yescarta (axicabtagene ciloleucel)
Drug company
• Kite Pharma
Indication
• Treatment of adults with relapsed or refractory follicular lymphoma who have received 2 or more lines of systemic therapy
Patient support services
• Kite Konnect
  844-454-5483

Drug name (generic name)
• Zevalin (ibritumomab tiuxetan)
Drug company
• Acrotech Biopharma
Indication
• Untreated follicular lymphoma
  
  Low-grade follicular lymphoma
Patient support services
• STAR Co-pay Assistance
  888-537-8277
  
  STAR Patient Assistance Program
  888-537-8277

Drug name (generic name)
• Zydelig (idelalisib) Tablets
Drug company
• Gilead
Indication
• Treatment of follicular lymphoma
Patient support services
• Zydelig AccessConnect Copay Coupon Card
  844-622-2377
  
  Zydelig AccessConnect Patient Assistance Program
  844-622-2377

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Brukinsa (zanubrutinib) Capsules
Drug company
• BeiGene
Indication
• Treatment of mantle-cell lymphoma
Patient support services
• BeiGene Co-pay Assistance
  833-234-4363
  
  BeiGene Bridge Supply Program
  833-234-4363
  
  BeiGene Free Product Assistance
  833-234-4363

Drug name (generic name)
• Calquence (acalabrutinib) Capsules
Drug company
• AstraZeneca
Indication
• Adults with mantle-cell lymphoma, after at least 1 therapy
Patient support services
• CALQUENCE Co-pay Savings Program
  844-275-2360
  
  AZ&Me Prescription Savings Program
  844-275-2360

Drug name (generic name)
• Imbruvica (ibrutinib) Capsules/Tablets
Drug company
• Pharmacyclics
Indication
• Mantle-cell lymphoma, after at least 1 therapy
Patient support services
• Imbruvica By Your Side Program
  888-968-7743
  
  Johnson & Johnson Patient Assistance Foundation
  800-652-6227

Drug name (generic name)
• Revlimid (lenalidomide) Capsules
Drug company
• Bristol Myers Squibb
Indication
• Treatment of relapsed or progressing mantlecell lymphoma, after 2 therapies, including Velcade
Patient support services
• BMS Oncology Co-pay Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Tecartus (brexucabtagene autoleucel)
Drug company
• Kite Pharma
Indication
• Treatment of adults with relapsed or refractory mantle-cell lymphoma
Patient support services
• Kite Konnect
  844-454-5483

Drug name (generic name)
• Velcade (bortezomib) Injection
Drug company
• Takeda Oncology
Indication
• Mantle-cell lymphoma
Patient support services
• Velcade Reimbursement Assistance Program
  844-817-6468

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Brukinsa (zanubrutinib) Capsules
Drug company
• BeiGene
Indication
• Treatment of adults with relapsed or refractory marginal-zone lymphoma who have received at least 1 anti-CD20–based regimen
Patient support services
• BeiGene Co-pay Assistance
  833-234-4363
  
  BeiGene Bridge Supply Program
  833-234-4363
  
  BeiGene Free Product Assistance
  833-234-4363

Drug name (generic name)
• Imbruvica (ibrutinib) Capsules/Tablets
Drug company
• Pharmacyclics
Indication
• Treatment of marginal-zone lymphoma, after at least 1 anti-CD20–based therapy in patients who require systemic therapy
Patient support services
• Imbruvica By Your Side Program
  888-968-7743
  
  Johnson & Johnson Patient Assistance Foundation
  800-652-6227

Drug name (generic name)
• Revlimid (lenalidomide) Capsules
Drug company
• Bristol Myers Squibb
Indication
• Treatment of marginal-zone lymphoma
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Calquence (acalabrutinib) Capsules
Drug company
• AstraZeneca
Indication
• Treatment of adults with SLL
Patient support services
• Calquence Co-pay Savings Program
  844-275-2360
  
  AZ&Me Prescription Savings Program
  844-275-2360

Drug name (generic name)
• Copiktra (duvelisib) Capsules
Drug company
• Secura Bio
Indication
• Treatment of relapsed or refractory SLL, after at least 2 therapies
Patient support services
• Co-Pay Program
  844-937-2872
  
  Secura Bio Quickstart Program
  844-937-2872

Drug name (generic name)
• Gazyva (obinutuzumab)
Drug company
• Genentech
Indication
• First-line treatment of SLL, in combination with Imbruvica
  
  First-line treatment of SLL, in combination with Venclexta
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Imbruvica (ibrutinib) Capsules/Tablets
Drug company
• Pharmacyclics
Indication
• First-line treatment of SLL, with or without 17p deletion
  
  First-line treatment of SLL, in combination with Gazyva
Patient support services
• Imbruvica By Your Side Program
  888-968-7743
  
  Johnson & Johnson Patient Assistance Foundation
  800-652-6227

Drug name (generic name)
• Venclexta (venetoclax) Tablets
Drug company
• AbbVie/Genentech
Indication
• Treatment of SLL, with or without 17p deletion
  
  First-line treatment of SLL, in combination with Gazyva or with rituximab
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Zydelig (idelalisib) Tablets
Drug company
• Gilead
Indication
• Treatment of relapsed SLL, after at least 2 systemic therapies
Patient support services
• Zydelig AccessConnect Copay Coupon Card
  844-622-2377
  
  Zydelig AccessConnect Patient Assistance Program
  844-622-2377